SEATTLE and CAMBRIDGE, Mass., Jan. 7, 2026 — InduPro, Inc., a biotechnology company that maps membrane protein spatial relationships to create therapeutics for cancer and autoimmune diseases, announced a global strategic collaboration and licensing agreement with Eli Lilly and Company, including an equity investment by Lilly.
Under the agreement, the companies will collaborate on up to three targets, with a total potential value of approximately $950 million. Lilly will gain access to InduPro’s proprietary AI/ML-enabled membrane interactomics (MInt) platform, while InduPro will lead early discovery efforts to identify co-target pairs and advance bispecific and multispecific antibody programs emerging from the collaboration.
The partnership will use InduPro’s proximity-guided platform to discover Tumor Associated Proximity Antigens (TAPAs) — surface proteins that are spatially co-localized and often functionally linked to tumor-associated antigens within the tumor microenvironment. The companies say this approach is intended to enable disease-specific protein-target pairings for bispecific antibody drug conjugates and multispecific T-cell engagers, aiming to improve safety, potency and tumor selectivity.
“TAPAs represent a fundamentally new way to think about tumor antigens, and we’re pleased that Lilly shares our vision of leveraging proximity-based biology to enable precision multi-specific therapeutics,” said Prakash Raman, PhD, CEO of InduPro. “This partnership reflects confidence in our proximity-guided approach to tumor targeting and its potential to improve the design and performance of ADCs and TCEs.”
About InduPro’s induced proximity approach
InduPro maps protein neighborhoods using proprietary, high-resolution proximity labeling technology to identify novel co-target pairs that are highly selective for specific disease biology. By therapeutically targeting cell surface proteins through inherent or induced proximity, the company seeks to influence cellular signaling pathways and generate potential first-in-class and best-in-class therapeutic candidates across multiple indications and modalities.
Leave a Reply